CytomX Therapeutics Inc (NASDAQ:CTMX) price on Tuesday, December 24, fall -1.83% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.07.
A look at the stock’s price movement, the close in the last trading session was $1.09, moving within a range at $1.06 and $1.1. The beta value (5-Year monthly) was 1.061 while the PE ratio in trailing twelve months stood at 6.31. Turning to its 52-week performance, $5.85 and $0.83 were the 52-week high and 52-week low respectively. Overall, CTMX moved 21.35% over the past month.
CytomX Therapeutics Inc’s market cap currently stands at around $82.20 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 13.53M for the company’s revenue for the quarter, with a low and high estimate of -15.3M and 33M respectively. The average forecast suggests down to a -49.14% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 115.72M, representing a 14.33% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CTMX is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 3 recommend CTMX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CTMX’s current price about -5.44% and 0.56% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 48.34, while 7-day volatility ratio is 7.50% and 8.98% in the 30-day chart. Further, CytomX Therapeutics Inc (CTMX) has a beta value of 1.03, and an average true range (ATR) of 0.09. Analysts have given the company’s stock an average 52-week price target of $3.465, forecast between a low of $3.25 and high of $3.68. Looking at the price targets, the low is -203.74% off current price level while to achieve the yearly target high, price needs to move -243.93%. Nonetheless, investors will most likely welcome a -223.83% jump to $3.465 which is the analysts’ median price.
If we refocus on CytomX Therapeutics Inc (NASDAQ:CTMX), historical trading data shows that trading volumes averaged 0.98 over the past 10 days and 1.15 million over the past 3 months. The company’s latest data on shares outstanding shows there are 78.23 million shares.
The 1.69% of CytomX Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 65.49% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.39 million on 2024-11-29, giving us a short ratio of 4.32. The data shows that as of 2024-11-29 short interest in CytomX Therapeutics Inc (CTMX) stood at 565.00003 of shares outstanding, with shares short falling to 5.67 million registered in 2024-10-31. Current price change has pushed the stock -30.32% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CTMX stock continues to rise going into the next quarter.
